Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer acquires manufacturing facility from Novartis
Bayer will manufacture Betaseron at the Emeryville site, retain full control of all manufacturing and process technology used in the production of Betaseron (interferon beta-1b) and has retained
Bayer will manufacture Betaseron at the Emeryville site, retain full control of all manufacturing and process technology used in the production of Betaseron (interferon beta-1b) and has retained
GSK had requested to initiate its review of XL880 before the compound reaches proof-of-concept as defined under the product development and commercialization agreement between the two companies. GSK
Ms Lacerca has experience in multi-jurisdictional corporate compliance, international business transactions, pharmaceutical industry regulation, corporate policy and international environmental law. She joins Mylan from Bristol-Meyers Squibb where she
Encysive received European marketing authorization for Thelin in August 2006. Thelin is the first selective endoThelin A receptor antagonist, and the first once-daily oral treatment available for patients
According to the company, this is the first approval for Dr Reddy's US over-the-counter (OTC) business to launch a Store Brand OTC Division in the US. Ranitidine is
Mr Junien has experience both in Europe and in the US in managing preclinical and clinical developments. Mr Motesharei is a former biotech executive with over 10 years
Johnson & Johnson’s subsidiary, Conor Medsystems, had attempted to revoke Angiotech’s New Zealand patent 523799, which pertains to compositions comprising a polymer and paclitaxel, as well as paclitaxel-eluting
The company also granted the underwriter a 30-day option to purchase up to an additional 1.05 million shares of common stock. Goldman, Sachs & Company acted as the
This phase II study is an international, multi-center, randomized, double- blind, controlled study in patients with complicated skin and skin structure infections (cSSSI) presumed or proven to be
Fentora is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying